Description:
<jats:title>Abstract</jats:title><jats:p>The purpose of this feasibility study was to select targeted therapies according to “ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)”. Data interpretation was further
supported by a browser-based Treatment Decision Support platform (MH Guide, Molecular Health, Heidelberg, Germany).</jats:p><jats:p>We applied next generation sequencing based whole exome sequencing of tumor tissue and peripheral blood of patients with metastatic breast cancer (n = 44) to detect somatic as well as
germline mutations.</jats:p><jats:p>In 32 metastatic breast cancer patients, data interpretation was feasible. We identified 25 genomic alterations with ESCAT Level of Evidence I or II in 18/32 metastatic breast cancer
patients, which were available for evaluation: three copy number gains in HER2, two gBRCA1, two gBRCA2, six PIK3CA, one ESR1, three PTEN, one
AKT1 and two HER2 mutations. In addition, five samples displayed Microsatellite instability high-H.</jats:p><jats:p>Resulting treatment options were discussed in a tumor board and could be recommended in a small but relevant proportion of patients with metastatic breast cancer (7/18). Thus, this study
is a valuable preliminary work for the establishment of a molecular tumor board within the German initiative “Center for Personalized Medicine” which aims to shorten time for analyses and
optimize selection of targeted therapies.</jats:p>